The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the completion of its business combination with First Light Acquisition Group (FLAG), a special purpose acquisition company. The common stock and warrants of Calidi are expected to commence trading on the New York Stock Exchange American under the ticker symbols “CLDI” and “CLDI WS,” respectively, on September 13, 2023. The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders. Calidi’s existing management team, including Chief Executive Officer and Chairman Allan Camaisa, will lead the combined company.

Press Release
event

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the completion of its business combination with First Light Acquisition Group (FLAG), a special purpose acquisition company. The common stock and warrants of Calidi are expected to commence trading on the New York Stock Exchange American under the ticker symbols “CLDI” and “CLDI WS,” respectively, on September 13, 2023. The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders. Calidi’s existing management team, including Chief Executive Officer and Chairman Allan Camaisa, will lead the combined company.

September 13, 2023
Discover More
Discover More
Press Release
event

Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference

Calidi Biotherapeutics, Inc., (approved for listing on NYSE American under “CLDI”), a clinical-stage biotechnology company that is developing a new generation of targeted immunotherapies, today announced that Allan Camaisa, CEO and Chairman of the Board, and Stephen Thesing, Chief Business Officer, will participate in a fireside chat at the upcoming Baird Global Healthcare Conference on Wednesday, September 13, 2023, at 7:55 a.m. ET.

September 12, 2023
Discover More
Discover More
Press Release
event

Calidi Biotherapeutics and City of Hope announce first patient dosed in a Phase 1 clinical trial evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients

City of Hope, one of the largest cancer research and treatment organizations in the United States and a National Cancer Institute-designated comprehensive cancer Center, and Calidi Biotherapeutics Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, today jointly announced that the first brain tumor patient was treated at City of Hope in a multicenter, Phase 1 clinical trial evaluating CLD-101, a leading-edge therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus — CRAd-S-pk7 — selectively to tumor sites.

July 18, 2023
Discover More
Discover More
Press Release
event

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer

Calidi Biotherapeutics, Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, today announced the commitment of $25 million in Series B funding led by Jackson Investment Group (“JIG”), who has funded an initial investment of $5 million, and participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi. The remaining commitment is conditioned upon the consummation of the previously announced business combination between First Light Acquisition Group (NYSEAMERICAN: FLAG) and Calidi.

June 23, 2023
Discover More
Discover More
Press Release
event

Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies

LA JOLLA, Calif. and RESTON, Va., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, and First Light Acquisition Group (“FLAG”) (NYSE American: FLAG), a special purpose acquisition company organized to acquire or merge

January 9, 2023
Discover More
Discover More
Press Release
event

Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs

December 13, 2022
Discover More
Discover More
Press Release

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the completion of its business combination with First Light Acquisition Group (FLAG), a special purpose acquisition company. The common stock and warrants of Calidi are expected to commence trading on the New York Stock Exchange American under the ticker symbols “CLDI” and “CLDI WS,” respectively, on September 13, 2023. The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders. Calidi’s existing management team, including Chief Executive Officer and Chairman Allan Camaisa, will lead the combined company.

September 13, 2023
Discover More
Press Release

Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference

Calidi Biotherapeutics, Inc., (approved for listing on NYSE American under “CLDI”), a clinical-stage biotechnology company that is developing a new generation of targeted immunotherapies, today announced that Allan Camaisa, CEO and Chairman of the Board, and Stephen Thesing, Chief Business Officer, will participate in a fireside chat at the upcoming Baird Global Healthcare Conference on Wednesday, September 13, 2023, at 7:55 a.m. ET.

September 12, 2023
Discover More
Press Release

Calidi Biotherapeutics and City of Hope announce first patient dosed in a Phase 1 clinical trial evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients

City of Hope, one of the largest cancer research and treatment organizations in the United States and a National Cancer Institute-designated comprehensive cancer Center, and Calidi Biotherapeutics Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, today jointly announced that the first brain tumor patient was treated at City of Hope in a multicenter, Phase 1 clinical trial evaluating CLD-101, a leading-edge therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus — CRAd-S-pk7 — selectively to tumor sites.

July 18, 2023
Discover More
Press Release

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer

Calidi Biotherapeutics, Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, today announced the commitment of $25 million in Series B funding led by Jackson Investment Group (“JIG”), who has funded an initial investment of $5 million, and participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi. The remaining commitment is conditioned upon the consummation of the previously announced business combination between First Light Acquisition Group (NYSEAMERICAN: FLAG) and Calidi.

June 23, 2023
Discover More
Press Release

Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies

LA JOLLA, Calif. and RESTON, Va., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, and First Light Acquisition Group (“FLAG”) (NYSE American: FLAG), a special purpose acquisition company organized to acquire or merge

January 9, 2023
Discover More
Press Release

Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs

December 13, 2022
Discover More
Press Release

Calidi Biotherapeutics to Present at the 7th Annual Oncolytic Virotherapy Summit

December 7, 2022
Discover More
Press Release

Calidi Biotherapeutics Presents Promising Pre-Clinical Data from SuperNova-1 (SNV1), a Novel Oncolytic-Cell Based Platform, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)

November 7, 2022
Discover More
Press Release

Calidi Biotherapeutics to Present Pre-Clinical SuperNova1 (SNV1) Data at the 2022 SITC Annual Meeting

October 12, 2022
Discover More
Press Release

Calidi Biotherapeutics Appoints David Sans, FAARM, Ph.D., MBA, as Head of Corporate Development

September 27, 2022
Discover More
Press Release

Calidi Biotherapeutics to Present at Two Upcoming Conferences

September 9, 2022
Discover More
Press Release

Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma

August 2, 2022
Discover More
Press Release

Calidi Biotherapeutics Announces Appointment of W.K. Alfred Yung, M.D., to its Medical Advisory Board

June 28, 2022
Discover More
Press Release

Calidi Biotherapeutics to Present at Jefferies Healthcare Conference

June 2, 2022
Discover More
Press Release

Calidi Biotherapeutics Granted US Patent for Proprietary Therapeutic Delivery Platform, Strengthening Company’s Intellectual Property Position in Immunotherapy

May 24, 2022
Discover More
Press Release

Calidi Biotherapeutics Announces Appointment of Alfonso "Chito" Zulueta, Former President of International for Eli Lilly, to Its Board of Directors

February 4, 2022
Discover More
Press Release

Calidi Biotherapeutics and Edoc Acquisition Corp. Agree to Merge and Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies

February 2, 2022
Discover More
Press Release

Calidi Biotherapeutics Announces Dr. Maciej S. Lesniak Presentation at 13th International Oncolytic Virotherapy Conference

November 5, 2021
Discover More
Press Release

Calidi Biotherapeutics Announces Presentation at 6th Annual Oncolytic Virotherapy Summit

October 25, 2021
Discover More
Press Release

Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy Technology

August 17, 2021
Discover More
Press Release

Calidi Biotherapeutics Announces Agreement with Northwestern University for Exclusive Commercial Rights to their IND for Treatment of Malignant Glioma

August 4, 2021
Discover More
Press Release

Calidi Biotherapeutics Announces Partnership with GenScript ProBio for Distribution of its SuperNova-1 Technology

June 9, 2021
Discover More
Press Release

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer

December 1, 2020
Discover More
Press Release

Calidi Biotherapeutics Announces FDA Approval for COVID-19 Treatment Manufactured by Partner, Personalized Stem Cells

August 3, 2020
Discover More
Press Release

Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors

July 1, 2020
Discover More
Press Release

Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at AACR 2020 Virtual Annual Meeting II

June 22, 2020
Discover More
Press Release

Stem Cells for COVID-19 | PSC Teams Up with Calidi Biotherapeutics

April 22, 2020
Discover More
Press Release

Calidi Biotherapeutics Announces Appointment of Dr. George Peoples, a Prominent Immuno-Oncology Expert, to its Scientific and Medical Advisory Board

February 27, 2020
Discover More
Press Release

Calidi Biotherapeutics Announces Appointment of Biotech Veteran Heehyoung Lee to Board of Directors

February 20, 2020
Discover More
Press Release

Calidi Biotherapeutics Presents Data at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium

February 13, 2020
Discover More
Press Release

Calidi Biotherapeutics Announces Abstract Acceptance For Presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium

February 3, 2020
Discover More
Press Release

Calidi Biotherapeutics Secures Series A Investments to Advance Manufacturing

January 22, 2020
Discover More
Press Release

The Mitchell Thorp Foundation Selects Calidi Biotherapeutics CEO to Receive the Pillars of Hope Award

December 19, 2019
Discover More
Press Release

Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

October 9, 2019
Discover More
Press Release

Calidi Biotherapeutics Named One of the “50 Most Trustworthy Companies of The Year 2019” by the Silicon Review Magazine

September 18, 2019
Discover More
Press Release

Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA

August 29, 2019
Discover More
Press Release

Calidi Biotherapeutics Announces the Appointment of Distinguished Biotech Innovator, Ewa Carrier, M.D., to Their Medical and Scientific Advisory Board

July 25, 2019
Discover More
Press Release

Calidi Biotherapeutics Announces Global Oncolytic Virus-based Immunotherapy License to VetStem Biopharma for its Pioneering Treatment of Cancer in the Veterinary Field

July 10, 2019
Discover More
Press Release

Calidi Biotherapeutics Announces The Appointment of Medical Oncologist and Expert in Oncolytic Immunotherapies, Dr. Dmitriy Zamarin to Their Scientific Advisory Board

June 3, 2019
Discover More
Press Release

Calidi Biotherapeutics Announces The Appointment Of Seasoned Biotech Executive Dr. Ashok Srivastava To Their Scientific Advisory Board

May 30, 2019
Discover More
Press Release

Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem Cells

May 28, 2019
Discover More
Press Release

Calidi Biotherapeutics Releases Recent Interviews of CEO Allan Camaisa

April 15, 2019
Discover More
Press Release

Calidi Biotherapeutics Launches Scientific and Medical Advisory Board

January 4, 2019
Discover More
Press Release

Calidi Biotherapeutics, Inc. announces its corporate vision in groundbreaking cancer drug development and appoints Allan Camaisa as CEO

January 1, 2019
Discover More
Press Release

Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

November 6, 2018
Discover More
Press Release

Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruses

October 25, 2018
Discover More
Publication
event

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial

Lancet Oncology

August 22, 2021
Discover More
Discover More
Publication
event

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

The Journal of Translational Medicine

May 18, 2020
Discover More
Discover More
Publication
event

ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8, 2020 Orlando, Florida.

Abstract 21: A cell-based platform to potentiate oncolytic virus therapies

February 6, 2020
Discover More
Discover More
Publication
event

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

The Journal of Translational Medicine

August 19, 2019
Discover More
Discover More
Publication
event

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P609: First in man study of TK positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

November 7, 2018
Discover More
Discover More
Publication
event

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P617: A cell-based platform to protect and enhance oncolytic virus therapies

November 7, 2018
Discover More
Discover More
Publication
event

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer | November 7-11, 2018 Washington, D.C.

November 7, 2018
Discover More
Discover More
Media

Good Morning San Diego, Calidi Bio Treatments Discussed

April 13, 2019
Discover More
Media

KUSI San Diego News - Calidi Bio CEO, Allan Camaisa Interviewed

April 12, 2019
Discover More

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more